Based on ratings from 13 stock analysts, the Array BioPharma Inc stock price is expected to increase by 70.24% in 12 months. This is calculated by using the average 12-month stock price forecast for Array BioPharma Inc. The lowest target is $15.00 and the highest is $35.00. Please note analyst price targets are not guaranteed and could be missed completely.
About 13 Wall Street analysts have assignedARRY 6 buy ratings, 7 hold ratings, and 0 sell ratings. This means that analysts expect Array BioPharma Inc to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ARRY. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
vikram bagri Citi | Hold | $16.5 | maintained | Jan 31, 2024 |
dushyant ailani Jefferies | Hold | $15.0 | maintained | Jan 30, 2024 |
jordan levy Truist Financial | Buy | $25.0 | maintained | Jan 23, 2024 |
christine cho cfa Barclays | Hold | $15.0 | downgraded | Jan 22, 2024 |
michael blum Wells Fargo | Hold | $19.0 | downgraded | Jan 8, 2024 |
maheep mandloi Mizuho Securities | Hold | $20.0 | maintained | Jan 3, 2024 |
donovan schafer cfa Northland Securities | Buy | $27.0 | maintained | Jan 3, 2024 |
julien dumoulin smith Bank of America Securities | Buy | $21.0 | maintained | Dec 26, 2023 |
joseph osha Guggenheim | Buy | $24.0 | maintained | Dec 19, 2023 |
kashy harrison Piper Sandler | Hold | $22.0 | downgraded | Dec 19, 2023 |
mark strouse J.P. Morgan | Buy | $35.0 | maintained | Dec 15, 2023 |
sean milligan Janney Montgomery | Buy | None | maintained | Dec 14, 2023 |
tristan richardson Scotiabank | Buy | $33.0 | maintained | Dec 11, 2023 |
andrew percoco Morgan Stanley | Hold | $19.0 | maintained | Dec 8, 2023 |
derek soderberg Cantor Fitzgerald | Buy | $22.0 | maintained | Nov 9, 2023 |
brian k. lee Goldman Sachs | Buy | $31.0 | reiterated | Nov 8, 2023 |
philip shen Roth MKM | Buy | $30.0 | maintained | Nov 8, 2023 |
jon windham UBS | Buy | $33.0 | maintained | Nov 8, 2023 |
thomas boyes TD Cowen | Hold | $22.5 | maintained | Nov 8, 2023 |
moses sutton Exane BNP Paribas | Hold | $21.0 | initiatedcoverage | Oct 20, 2023 |
Array Technologies, Inc. manufactures and sells ground-mounting tracking systems used in solar energy projects in the United States, Spain, Brazil, Australia, and internationally. The company operates in two segments, Array Legacy Operations and STI Operations. Its products include DuraTrack HZ v3, a single axis tracker; Array STI H250 to deliver a lower levelized cost of energy with tracker system; Array OmniTrack; and SmarTrack, a software product that uses site-specific historical weather and energy production data in combination with machine learning algorithms to identify the optimal position for a solar array in real time to enhance its energy production. The company was founded in 1989 and is headquartered in Albuquerque, New Mexico.
When did it IPO
2020
Staff Count
1,058
Country
United States
Sector/Industry
Technology/Solar
CEO
Mr. Kevin G. Hostetler
Market Cap
$2.16B
In 2023, ARRY generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ARRY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
DNUT-USD
$13.32
ACVA-USD
$16.41
BLMN-USD
$26.6
$33.02
CORT-USD
$21.66
NMIH-USD
$29.05